Mechanisms involved in the vasorelaxant effects produced by the acute application of amfepramone in vitro to rat aortic rings

Amfepramone (diethylpropion) is an appetite-suppressant drug used for the treatment of overweight and obesity. It has been suggested that the systemic and central activity of amfepramone produces cardiovascular effects such as transient ischemic attacks and primary pulmonary hypertension. However, it is not known whether amfepramone produces immediate vascular effects when applied in vitro to rat aortic rings and, if so, what mechanisms may be involved. We analyzed the effect of amfepramone on phenylephrine-precontracted rat aortic rings with or without endothelium and the influence of inhibitors or blockers on this effect. Amfepramone produced a concentration-dependent vasorelaxation in phenylephrine-precontracted rat aortic rings that was not affected by the vehicle, atropine, 4-AP, glibenclamide, indomethacin, clotrimazole, or cycloheximide. The vasorelaxant effect of amfepramone was significantly attenuated by NG-nitro-L-arginine methyl ester (L-NAME) and tetraethylammonium (TEA), and was blocked by removal of the vascular endothelium. These results suggest that amfepramone had a direct vasorelaxant effect on phenylephrine-precontracted rat aortic rings, and that inhibition of endothelial nitric oxide synthase and the opening of Ca2+-activated K+ channels were involved in this effect.

Combined effects of diethylpropion and alcohol on locomotor activity of mice: participation of the dopaminergic and opioid systems

The widespread consumption of anorectics and combined anorectic + alcohol misuse are problems in Brazil. In order to better understand the interactive effects of ethanol (EtOH) and diethylpropion (DEP) we examined the locomotion-activating effects of these drugs given alone or in combination in mice. We also determined whether this response was affected by dopamine (DA) or opioid receptor antagonists. A total of 160 male Swiss mice weighing approximately 30 g were divided into groups of 8 animals per group. The animals were treated daily for 7 consecutive days with combined EtOH + DEP (1.2 g/kg and 5.0 mg/kg, ip), EtOH (1.2 g/kg, ip), DEP (5.0 mg/kg, ip) or the control solution coadministered with the DA antagonist haloperidol (HAL, 0.075 mg/kg, ip), the opioid antagonist naloxone (NAL, 1.0 mg/kg, ip), or vehicle. On days 1, 7 and 10 after the injections, mice were assessed in activity cages at different times (15, 30, 45 and 60 min) for 5 min. The acute combination of EtOH plus DEP induced a significantly higher increase in locomotor activity (day 1: 369.5 + or - 34.41) when compared to either drug alone (day 1: EtOH = 232.5 + or - 23.79 and DEP = 276.0 + or - 12.85) and to control solution (day 1: 153.12 + or - 7.64). However, the repeated administration of EtOH (day 7: 314.63 + or - 26.79 and day 10: 257.62 + or - 29.91) or DEP (day 7: 309.5 + or - 31.65 and day 10: 321.12 + or - 39.24) alone or in combination (day 7: 459.75 + or - 41.28 and day 10: 427.87 + or - 33.0) failed to induce a progressive increase in the locomotor response. These data demonstrate greater locomotion-activating effects of the EtOH + DEP combination, probably involving DA and/or opioid receptor stimulation, since the daily pretreatment with HAL (day 1: EtOH + DEP = 395.62 + or - 11.92 and EtOH + DEP + HAL = 371.5 + or - 6.76; day 7: EtOH + DEP = 502.5 + or - 42.27 and EtOH + DEP + HAL = 281.12 + or - 16.08; day 10: EtOH + DEP = 445.75 + or - 16.64 and EtOH + DEP + HAL = 376.75 + or - 16.4) and NAL (day 1: EtOH + DEP = 553.62 + or - 38.15 and EtOH + DEP + NAL = 445.12 + or - 55.67; day 7: EtOH + DEP = 617.5 + or - 38.89 and EtOH + DEP + NAL = 418.25 + or - 61.18; day 10: EtOH + DEP = 541.37 + or - 32.86 and EtOH + DEP + NAL = 427.12 + or - 51.6) reduced the locomotor response induced by combined administration of EtOH + DEP. These findings also suggest that a major determinant of combined anorectic-alcohol misuse may be the increased stimulating effects produced...

Involvement of dopamine receptors in diethylpropion-induced conditioning place preference

Diethylpropion (DEP) is an amphetamine-like agent used as an anorectic drug. Abuse of DEP has been reported and some restrictions of its use have been recently imposed. The conditioning place preference (CPP) paradigm was used to evaluate the reinforcing properties of DEP in adult male Wistar rats. After initial preferences were determined, animals weighing 250-300 g (N= 7 per group) were conditioned with DEP (10, 15 or 20 mg/kg). Only the dose of 15 mg/kg produced a significant place preference (358 + 39 vs 565 + 48s). Pretreatment with the D1 antagonist SCH 23390 (0.05 mg/kg, sc) 10 min before DEP (15 mg/kg, ip) blocked DEP-induced CPP (418 + 37 vs 389 + 31 s) while haloperidol (0.5 mg/kg, ip), a D2 antagonist, 15 min before DEP was ineffective in modifying place conditioning produced by DEP (385 + 36 vs 536 + 41 s). These results suggest that dopamine D1 receptors mediate the reinforcing effect of DEP.

Dietilpropiona, Femproporex, Diazepam e Fenolftaleina: determinacao em formulacoes para emagrecimento / Diethylpropion, Femproporex, Diazepam and Phenolphtalein: determination in formulation for slim

Com o objetivo de analisar dietilpropiona, femproporex, diazepam e fenolftaleina em formulacoes para regime de emagrecimento, foi desenvolvido um metodo de separacao e determinacao destas substancias, utilizando procedimentos volumetricos e espectrofotometricos nas regioes do ultravioleta e visivel